Evosep Biosystems(EVOSEP) 🇩🇰
Evosep develops new solutions to make clinical proteomics 100 times more robust and 10 times faster. We are targeting the growing need for throughput with robust solutions for clinical and large-scale proteomics, and we have a very ambitious business plan to bring our first products to market. We are basing our design on years of experience with nano-UHPLC R&D and application support, critically rethinking the necessary system architectures for successful sample separation before mass spectrometric analysis. Evosep aims to improve the quality of life and patient care by radically innovating how protein based clinical diagnostics are performed, initially through collaborations with world-leading scientists about developing new technologies and solutions to make sample separation 10 times faster and 100 times more robust than todays’ alternatives. Proteomics is about the study of proteins in a biological mechanism, both their individual function and their combined interactions. For clinical proteomics the goal is to be able to quickly and efficiently compare a biological sample against a profile panel of selected proteins in order to deliver a diagnose / verdict of healthy or diseased (within given statistical margins). Such a profile is typically called a biomarker and for official approval, it must be demonstrated successfully on a large population.
Ole Vorm 🇩🇰
Ole Vorm, Founder and Director of Evosep. He is a serial entrepreneur that started his first company as a spin-off from a post-doc in Heidelberg in 1997. Since then, Ole has worked inside Sciex, Thermo Scientific and Bruker in various roles leading chromatography and mass spectrometry products into new markets and applications.